Onglyza and Kombiglyze XR lawsuits blame the drugs for causing cardiac injuries. In February 2018, a federal panel consolidated lawsuits against Bristol-Myers Squibb and AstraZeneca in federal court in Kentucky. There have not yet been any publicized settlements or verdicts.
If you took Onglyza or Kombiglyze XR and suffered from heart related side effects, you may be entitled to compensation.
People are suing Bristol-Myers Squibb and AstraZeneca over the Type 2 diabetes drugs Onglyza (saxagliptin) and Kombiglyze XR (saxagliptin and metformin HCI extended release). Lawsuits allege these drugs caused serious cardiac complications and sometimes death.
In February 2018, a federal panel consolidated cases from several different states into a single litigation in Kentucky. As of Feb. 15, 2018, 84 cases were pending in the U.S. District Court for the Eastern District of Kentucky.
Recent lawsuits allege saxagliptin can cause heart failure, congestive heart failure, cardiac failure and death. According to these claims, Bristol Myers Squibb and AstraZeneca failed to warn doctors and patients of the risk.
Attorneys are currently accepting lawsuits from people who suffered heart failure or congestive heart failure, cardiac failure before April 5, 2016. Lawsuits may also be filed by people whose loved ones died before that date and were taking Onglyza or Kombiglyze XR at the time.
If you or a loved one were diagnosed with Type 2 diabetes and started taking Onglyza or Kombiglyze XR between July 2009 and April 5, 2016, you may be able to seek compensation through a lawsuit if you or your loved one developed the following complications:
Some of the first Onglyza and Kombiglyze XR lawsuits filed against AstraZeneca and Bristol-Myers Squibb involve pancreatitis — inflammation of the pancreas — and pancreatic cancer.
“In May 2016, a federal judge in California granted AstraZeneca’s motion for summary judgment and dismissed the claims of 14 plaintiffs who alleged pancreatic injuries, including pancreatic cancer, from treatment with either Onglyza or Kombiglyze. No similar claims remain actively pending in any U.S. jurisdiction.”
Some lawyers may still be taking cases for pancreatic cancer or pancreatitis, but the primary focus for Onglyza and Kombiglyze XR litigation involves heart failure.
In various lawsuits, plaintiffs allege the manufacturers of Onglyza and Kombiglyze XR didn’t tell doctors and patients about dangerous side effects and didn’t properly test the drugs before selling them.
Plaintiffs filing lawsuits say Type 2 diabetes drugs Onglyza (saxagliptin) and Kombiglyze XR (saxagliptin and metformin extended release) made by Bristol-Myers Squibb and AstraZeneca caused serious side effects including heart failure, heart attack and death.
The main defendants named in these lawsuits are Bristol-Myers Squibb, AstraZeneca and Amylin Pharmaceuticals, LLC — a wholly owned subsidiary of AstraZeneca. Other named defendants include IPR Pharmaceuticals and McKesson Corp., companies that may have been involved in distribution, manufacturing and marketing of Onglyza and Kombiglyze XR. Plaintiffs allege the companies failed to adequately study the drugs and then hid risks of serious side effects from the public.
There have been no verdicts or publicized settlements in cases involving Onglyza and Kombiglyze XR because the cases alleging their link to serious cardiac injuries are still making their way through the early stages of litigation.
But Onglyza and Komgiglyze XR are only the latest of a number of diabetes drugs that have been the focus of lawsuits. Other companies have been forced to pay hundreds of millions to settle similar litigation.
There are currently no known class action lawsuits for Onglyza and Kombiglyze XR. But, on Feb. 2, 2018, judges consolidated cases from 23 districts into multidistrict litigation (MDL) No. 2809.
Consolidation allows courts to manage large numbers of similar lawsuits filed against the same defendants. It allows a single judge to issue pre-trial rulings that apply to all of the consolidated cases.
MDL 2809 is in the Eastern District of Kentucky. Chief Judge Karen K. Caldwell is presiding over the cases.
The MDL covers injuries such as heart failure, congestive heart failure, myocardial infarction and cardiovascular injury.
There is also a motion seeking to consolidate cases in California State Court.
Typically, in MDL and state court consolidated actions, the parties will select a few cases to go to trial first — known as bellwethers — so that both the plaintiffs and the defense will gain an understanding on how other cases may play out. This information can be used to inform potential settlement negotiations.
No bellwether trials had been set as of February 2018.
Please seek the advice of a medical professional before making health care decisions.
Calling this number connects you with Wilson and Peterson, LLP or one of its trusted legal partners. A law firm representative will review your case for free.
Wilson and Peterson, LLP funds Drugwatch because it supports the organization’s mission to keep people safe from dangerous drugs and medical devices.(866) 343-0328